

Clinical Observation on the Target Therapy of Rh-Endostin, Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer

Haiyu MU, Chunyan SHEN, Yiling FENG

摘要

Background and objective The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the target therapy of rh-Endostin combined with chemotherapy in patients with advanced NSCLC. **Methods** Sixty-two advanced NSCLC patients were randomly divided into either the trial group with chemotherapy plus rh-Endostin or control group with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria. **Results** The trial groups efficiency rate was 46.87%, while the control group was 26.66%, there was no significant differences of two groups ($\chi^2=1.912$, $P=0.166$). The clinical benefit rate was 81.25% in the trial group and 53.33% in control group. There was significant difference of the clinical benefit rate between the trial group and the control group ($\chi^2=4.3185$, $P=0.0377$). The score of quality of life in the trial group was significantly higher than that the control group after the treatment ($\chi^2=11.233$, $P=0.0008$). There was no significant difference of incidence of toxicities between the trial group and the control group ($P>0.05$). **Conclusion** Rh-Endostin combined with chemotherapy was effective, reasonable, safe and well tolerated for advanced NSCLC.

全文: [PDF](#) [HTML](#)



ARTICLE TOOLS

- 索引源数据
- 如何引证项目
- 查找参考文献
- 审查政策
- Email this article
(Login required)

RELATED ITEMS

Related studies
[Databases](#)
[Web search](#)
 Show all

ABOUT THE AUTHORS

Haiyu MU

Chunyan SHEN

Yiling FENG



